Active — Not RecruitingPhase 4

Connective Tissue Matrix for Rotator Cuff Tendinopathy

United States92 participantsStarted 2023-12-04

Plain-language summary

The purpose of this research study is to determine if the effectiveness of a single injection of CTM Boost in the treatment of patients with rotator cuff tendinopathy (RCT) is as effective as a single injection of platelet rich plasma (PRP) in reducing the symptoms of RCT.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18-80 years old with rotator cuff tendinopathy * A PRP or CTM-type injection was determined by the clinician to be the proper medical treatment course and patient is willing to undergo the injection Exclusion Criteria: * Patients with adhesive capsulitis * Patients with acromio-clavicular joint impingement, retracted tears, significant labral lesions or significant glenohumeral arthrosis * Patients with joint instability * History of shoulder surgery or corticosteroid injection in the past 3 months * Patients with any medical conditions that affect healing, such as end-stage renal disease or uncontrolled diabetes

What they're measuring

determine if injection of CTM Boost is non-inferior to injection of PRP

Timeframe: 6 months

Trial details

NCT IDNCT06160427

SponsorAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-01-15

View on ClinicalTrials.gov More Tendinopathy trials